表紙
企業レポート

競合分析:血液凝固因子

Competitor Analysis: Coagulation Factors

発行 La Merie Publishing 商品コード 102247
出版日 ページ情報 英文 158 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
競合分析:血液凝固因子 Competitor Analysis: Coagulation Factors
出版日: 2013年05月04日 ページ情報: 英文 158 Pages
概要

血液凝固因子VIII、IXおよびVIIaの主要組み換えブランド6製品の世界的な売上は、2012年に72億米ドルとなりました。

当レポートでは、遺伝性/後天性の血液凝固障害治療における局所性/全身投与向け血漿由来/組み換え血液凝固因子製剤の分野について競合評価を提供しており、概略以下の構成でお届けします。

目次

  • 血友病向け組み換え凝固因子の売上
  • ヒト血漿由来凝固因子VIII濃縮剤
  • 組み換え凝固因子IX
  • ヒト血漿由来因子VII
  • 組み換え凝固因子VII
  • ヴィレブランド病向けヒト血漿由来凝固因子濃縮剤
  • 組み換えヒトフォンヴィレブランド因子(vWF)
  • ヒト血漿由来フィブリノゲン
  • 組み換えヒトフィブリノゲン
  • ヒト血漿由来因子XI
  • ヒト血漿由来因子X
  • 組み換えヒト因子X
  • ヒト血漿由来因子XIII
  • 組み換えヒト因子XIII
  • 代替凝結促進剤・補助剤
  • ヒト血漿由来プロトロンビン複合体濃縮製剤
  • 血友病の遺伝子治療
  • 局所的ヒト血漿由来フィブリノゲン複合体濃縮剤
  • 局所血漿由来プロトロンビン複合体濃縮剤
  • 局所的組み換えヒト因子II(プロトロンビン)
  • 代替局所止血薬
  • 企業の凝固因子製品ポートフォリオおよびR&Dパイプライン

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: LMCA0027

The Competitive Intelligence Report ‘Coagulation Factors‘ provides a competitor analysis of plasma-derived and recombinant coagulation factors for topical or systemic administration to treat hereditary or acquired coagulation disorders as of May 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Global sales of the six major recombinant branded products of coagulation factors VIII, IX and VIIa in 20012 were US$ 7.2 bln. This attractive market size and the soon beginning expiration of basic patents stimulated established hemophilia product companies as well as companies with new technologies to enter the race for next generation systemic coagulation factor products. Projects have rapidly progressed in clinical trials and several of them are already under regulatory review.

Apart from recombinant products, plasma-derived coagulation factors still play a considerable role, albeit bovine derived products are considerably being challenged by human recombinant and human plasma-derived products. Coagulation factors not only are being used for systemic treatment of hereditary coagulation factor deficiencies, but also for topical or systemic treatment of bleedings.

The report includes a compilation of current active projects in research and development of topical and systemic coagulation factors obtained by purification of human plasma or by recombinant DNA technology. In addition, the report lists company-specific product portoflios and R&D pipelines of coagulation factors.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

  • Sales of Recombinant Coagulation Factors for Hemophilia in 2012
  • Human Plasma-Derived Coagulation Factor VIII Concentrates
  • Recombinant Coagulation Factor VIII
  • Human Plasma-Derived Coagulation Factor IX
  • Recombinant Coagulation Factor IX
  • Human Plasma-Derived Factor VII
  • Recombinant Coagulation Factor VII
  • Human Plasma-Derived Coagulation Factor Concentrates for Willebrand Disease
  • Recombinant Human von Willebrand Factor (vWF)
  • Human Plasma-Derived Fibrinogen
  • Recombinant Human Fibrinogen
  • Human Plasma-Derived Factor XI
  • Human Plasma-Derived Factor X
  • Recombinant Human Factor X
  • Human Plasma-Derived Factor XIII
  • Recombinant Human Factor XIII
  • Alternative Procoagulants & Adjuncts
  • Human Plasma-Derived Prothrombin Complex Concentrates
  • Gene Therapy of Hemophilia
  • Topical Human Plasma-Derived Fibrinogen and Thrombin Products
  • Topical Plasma-Derived Thrombin Products
  • Topical Recombinant Human Factor II (Prothrombin)
  • Alternative Topical Hemostats
  • Corporate Coagulation Factor Product Portfolios and R&D Pipelines
Back to Top